You may have heard of NuSil—the “ceiling” of global medical silicone, a long-established powerhouse in high-performance materials from DuPont, and Norway’s Elkem, which has focused on upstream silicone and medical-grade silicone rubber for many years. But you might not know: these giants, each with annual revenues in the tens of billions of dollars, have all continuously commissioned the core components of long-term implantable silicone—such as infusion port sealing parts, base assemblies, and drug channel sealing rings—to a Chinese company: Jingwei Nano.
Not trial orders, not small-batch validation, but stable cooperation lasting more than five years; It’s not ordinary silicone, but rather ‘implant-grade silicone’ that is directly implanted in the body and left in place for months or even years. This sounds a bit counterintuitive: why don’t top foreign companies do their own business? Why choose a local Chinese company? Today, let’s break it down and say something honest.
So the answer is clear: NuSil, DuPont, and Elkem chose Jingwei Nano not because it is “cheap in China,” but because Jingwei Nano is a partner that can simultaneously meet the needs of “ultra-clean production + full bioverification + dual certification system + rapid process iteration + deep data traceability.”